Macular Degeneration
Conditions
Brief summary
To evaluate the scotopic and photopic ERG responses before and after one month of intravitreal avastin injection in patients with choroidal neovascularization. A positive finding that will reveal a toxic effect of intravitreal avastin injection on any component of the retina will have a significant important clinical impact regarding the decision whether the benefit of avastin treatment for CNV will prevail over toxic effect.
Detailed description
The study will include 20 patients who are diagnosed with CNV and were submitted for intravitreal injection of avastin. Patients with uncontrolled glaucoma, any ocular operation two months prior to the injection, ocular inflammatory disease, systemic hypertension treated with more than one medication, myocardial infarct, congestive heart disease will not be included in the study. After the patient will approve to participate in the study and will fall in with the inclusion and exclusion criteria, the patient will sign a written consent statement (enclosed). Medical history and ophthalmic examination will be written in the study file. The patients will undergo the full-field ERG test using the ISCEV Protocol. Since the ERG is a non invasive test the patient will be admitted on the same day for intravitreal avastin in the designated eye. After one month the patient will undergo identical ERG protocol in addition to the standard follow-up examinations protocol for intravitreal avastin injection (1 day, 1 week, 1 month). The other eye will serve as control group.
Interventions
PROCEDUREELECTRORETINOGRAM
Bevacizumab 1.25 mg/0.05 ml unilaterally into the vitreous cavity as part of the standard management for choroidal neovascular AMD. ERG responses form both eyes will be measured at baseline and 1 month after intravitreal injection
Sponsors
Sheba Medical Center
Study design
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
50 Years to 85 Years
Healthy volunteers
No
Inclusion criteria
1. Patients who were diagnosed with CNV caused by ARMD 2. ERG can be performed in both eyes
Exclusion criteria
1. Treatment within 7 days with VERTOPROFIN 2. Treatment within one month with laser photocoagulation 3. Ocular surgery for AMD (besides laser). 4. Participation in other medical study 5. Sub-fovea RPE atrophy in the study eye. 6. CNV with ocular histoplasmosis, trauma, pathological myopia. 7. Uveitis or history of uveitis. 8. Retinal pigment epithelium tear in the fovea of the injected eye. 9. Vitreous hemorrhage 10. Conjunctivitis, keratitis, scleritis, endophthalmitis. 11. Intraocular surgery (including cataract) within two months 12. Uncontrolled glaucoma (IOP≥30 mmHg under glaucoma medications) 13. Hypertension treated with two or more medication 14. History of myocardial infarct 15. History of myocardial insufficiency -
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| electroretinogram responses | before treatment and one month after treatment |
Countries
Israel
Outcome results
None listed